Quality of clinical practice guidelines for glycemic control in type 2 diabetes mellitus.

Quality of clinical practice guidelines for glycemic control in type 2 diabetes mellitus.
复制标题

DOI:
10.1371/journal.pone.0058625
复制
发表时间:
2013
期刊:
影响因子:
3.7
通讯作者:
Norris SL
Norris SL
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Holmer HK;Ogden LA;Burda BU;Norris SL

文献摘要

参考文献

被引文献

相似文献

一些研究报告,临床实践指南(CPGs)在各种临床领域是中等或可变的质量。本研究的目的是评估国际队列cpg的质量,为2型糖尿病(DM2)患者血糖控制的药物管理提供建议。我们于2012年2月15日和6月4日在国家指南信息中心(National guidelines Clearinghouse, NGC)检索符合纳入标准的cpg。两名独立评估人员使用研究与评估指南II (AGREE II)工具对每个CPG的质量进行评估。24条指导方针被评估,大多数在清晰度和表达方面得分很高。然而,范围和目的、涉众参与、开发的严谨性和适用性领域差异很大。大多数指南在编辑独立性上得分很低,只有7个cpg是基于对证据的潜在系统评价。DM2患者血糖控制cpg的总体质量是中等的,但在指南内部和不同指南之间的质量领域存在很大的差异。指南使用者需要意识到这种可变性,并仔细评估和选择他们应用于患者护理的指南。
Several studies have reported that clinical practice guidelines (CPGs) in a variety of clinical areas are of modest or variable quality. The objective of this study was to evaluate the quality of an international cohort of CPGs that provide recommendations on pharmaceutical management of glycemic control in patients with type 2 diabetes mellitus (DM2). We searched the National Guideline Clearinghouse (NGC) on February 15th and June 4th, 2012 for CPGs meeting inclusion criteria. Two independent assessors rated the quality of each CPG using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument. Twenty-four guidelines were evaluated, and most had high scores for clarity and presentation. However, scope and purpose, stakeholder involvement, rigor of development, and applicability domains varied considerably. The majority of guidelines scored low on editorial independence, and only seven CPGs were based on an underlying systematic review of the evidence. The overall quality of CPGs for glycemic control in DM2 is moderate, but there is substantial variability among quality domains within and across guidelines. Guideline users need to be aware of this variability and carefully appraise and select the guidelines that they apply to patient care.
DOI: 10.1016/j.jclinepi.2010.12.005
发表时间: 2011-09-01
影响因子: 7.2
作者:
Burda, Brittany U.;Norris, Susan L.;Smith, M. E. Beth
通讯作者: Smith, M. E. Beth
DOI: 10.3747/co.19.930
发表时间: 2012-06-01
期刊: CURRENT ONCOLOGY
影响因子: 2.6
作者:
Hogeveen, S. E.;Han, D.;Simmons, C. E.
通讯作者: Simmons, C. E.
DOI: 10.1378/chest.123.1_suppl.7s
发表时间: 2003-01-01
期刊: CHEST
影响因子: 9.6
作者:
Harpole, LH;Kelley, MJ;McCrory, DC
通讯作者: McCrory, DC
DOI: 10.1200/jco.2004.06.157
发表时间: 2004-05-15
影响因子: 45.3
作者:
Burgers, JS;Fervers, B;Cluzeau, FA
通讯作者: Cluzeau, FA
DOI: 10.4158/ep.17.s2.1
发表时间: 2011-03-01
期刊: ENDOCRINE PRACTICE
影响因子: 4.2
作者:
Handelsman, Yehuda;Mechanick, Jeffrey I.;Wyne, Kathleen L.
通讯作者: Wyne, Kathleen L.